Back to Search Start Over

Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity

Authors :
Xinxin Zhang
Yuxi Sun
Yanli Zhang
Fengqi Fang
Jiwei Liu
Yunlong Xia
Ying Liu
Source :
Journal of Cardiovascular Development and Disease, Vol 9, Iss 11, p 372 (2022)
Publication Year :
2022
Publisher :
MDPI AG, 2022.

Abstract

Cardiotoxicity is one of the major side effects of anti-cancer therapy affecting the overall prognosis of patients and possibly leading to the discontinuation of chemotherapy. Traditional cardiovascular tests such as electrocardiography and transthoracic echocardiography have limited sensitivity and specificity for the early detection of myocardial injury. Cardiovascular imaging generally detects cancer therapy-related cardiac dysfunction (CTRCD) at advanced stages, whereas biomarkers are inexpensive, easily detected, reproducible, and capable of detecting even minimal cardiomyocyte damage or mild hemodynamic fluctuations. The presence of circulating cardiac biomarkers has been investigated as early indicators of cardiotoxicity and predictors of subsequent CTRCD. Currently, the most frequently used cardiac biomarkers are cardiac troponin (cTn) and natriuretic peptides (NPs). This review presents the evidence gathered so far regarding the usefulness and limitations of cardiac biomarkers in the field of cardio-oncology.

Details

Language :
English
ISSN :
23083425
Volume :
9
Issue :
11
Database :
Directory of Open Access Journals
Journal :
Journal of Cardiovascular Development and Disease
Publication Type :
Academic Journal
Accession number :
edsdoj.f801a7dd29084fa58a1f3b96007381a1
Document Type :
article
Full Text :
https://doi.org/10.3390/jcdd9110372